Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Arterioscler Thromb Vasc Biol ; 17(6): 1024-31, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9194750

ABSTRACT

We recently reported that the human monocytic Mono Mac 6sr cell line constitutively takes up and degrades acetylated (acLDL) and oxidized LDL through receptor-specific pathways. The present studies were undertaken to further characterize the acLDL binding site on a functional and molecular basis. The degradation of acLDL increased during differentiation of Mono Mac 6sr cells with lipopolysaccharide (10 ng/mL, 72 hours) and low concentrations of phorbol 12-myristate 13-acetate (PMA; 0.1 to 1.0 ng/mL, 72 hours). Higher doses of PMA (5 or 10 ng/mL), however, decreased acLDL degradation. Scatchard plots of acLDL binding in untreated and LPS-differentiated Mono Mac 6sr cells were nonlinear and suggested the presence of more than one binding site. Although the ligand specificity of the acLDL receptor in Mono Mac 6sr cells resembles that of the macrophage type I and type II scavenger receptors, we did not detect mRNA of either receptor type in untreated or differentiated Mono Mac 6sr cells by means of Northern blotting and reverse transcription polymerase chain reaction. Furthermore, ligand blotting with 125I-acLDL failed to detect the 220-kD types I and II scavenger receptor protein. Thus, Mono Mac 6sr cells express an acLDL receptor that is distinct from the type I and type II scavenger receptor found in human monocyte-derived macrophages but that, like the latter, is induced during monocytic differentiation.


Subject(s)
Lipoproteins, LDL/metabolism , Membrane Proteins , Monocytes/metabolism , Receptors, Immunologic/metabolism , Receptors, Lipoprotein , Cell Differentiation , Cell Line , Cholesterol/metabolism , Endocytosis , Gene Expression , Humans , Ligands , Monocytes/cytology , RNA, Messenger/genetics , Receptors, Immunologic/genetics , Receptors, Scavenger , Scavenger Receptors, Class B
2.
Arterioscler Thromb Vasc Biol ; 15(8): 1131-8, 1995 Aug.
Article in English | MEDLINE | ID: mdl-7627706

ABSTRACT

Native LDL and LDL oxidized under various conditions were compared in terms of their ability to activate platelets. Native LDL did not induce platelet shape change or aggregation, even at high concentrations (2 mg protein/mL). LDL was mildly oxidized with either CuSO4 (mox-LDL) or 3-(N-morpholino)sydnonimine (SIN-1-LDL). Analysis of mox-LDL and SIN-1-LDL showed a small increase of dienes (E234nm from 0.28 +/- 0.04 to 0.55 +/- 0.09, mean +/- SD) and thiobarbituric acid-reactive substance (from 0 to 10.6 +/- 1.5 nmol/mg, mean +/- SEM), no change in apo B electrophoretic mobility, and a minor (12% to 30%) decrease in polyunsaturated fatty acid content. Interestingly, this small oxidative modification of LDL dramatically changed its effect on platelets. Irreversible aggregation and secretion were induced by a threshold concentration of 0.4 mg protein/mL. In contrast, LDL thoroughly oxidized with CuSO4 (ox-LDL) did not aggregate platelets. Although mox-LDL was depleted in antioxidants (alpha- and gamma-tocopherol, alpha- and beta-carotene, and other carotenoids), incubation of mox-LDL with exogenous alpha-tocopherol did not reverse its ability to induce platelet aggregation and secretion. Preincubation of platelets with the cyclooxygenase inhibitor aspirin or the phospholipase A2 inhibitors trifluoperazine, quinacrine, 4-bromophenacyl bromide, and propranolol completely prevented platelet aggregation and secretion caused by mox-LDL or SIN-1-LDL. These results indicate that mildly oxidized LDL activates platelets through a phospholipase A2/cyclooxygenase-dependent pathway. The complete inhibition of mox-LDL-induced platelet aggregation by aspirin could contribute to its beneficial effect in cardiovascular disease.


Subject(s)
Blood Platelets/physiology , Lipoproteins, LDL/chemistry , Phospholipases A/metabolism , Platelet Aggregation/drug effects , Adenosine Triphosphate/metabolism , Antioxidants/pharmacology , Apolipoproteins B/chemistry , Enzyme Activation , Fatty Acids/chemistry , Humans , In Vitro Techniques , Lipoproteins, LDL/pharmacology , Oxidation-Reduction , Phospholipases A2
3.
Am J Kidney Dis ; 25(4): 564-71, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7702051

ABSTRACT

Contact to artificial surfaces during hemodialysis activates leukocytes, which then form oxidized arachidonic acid products and free radicals. This might promote the oxidative modification of low-density lipoproteins (LDL) that play a key role in the initiation of atherosclerosis. Thus, leukocyte activation could specifically contribute to the high mortality from atherosclerotic complications on long-term hemodialysis. Therefore monitored LDL and high-density lipoprotein (HDL) resistance to copper-stimulated oxidation in patients with end-stage renal disease on maintenance hemodialysis with cellulose acetate or polysulfone membranes (n = 12), in patients with chronic renal failure (n = 13) and in healthy controls (n = 12). Six of the dialysis patients were restudied during a single cuprophane dialysis. Circulating leukocytes were reversibly reduced early in hemodialysis with cellulose acetate (minimum, 83.6% +/- 7.4% of baseline values at 30 minutes after dialysis start), polysulfone (minimum, 80.4% +/- 10.5% at 15 minutes; P < 0.05) and cuprophane (minimum, 24.5% +/- 8.5% at 60 minutes; P < 0.0001). Despite the leukocyte activation, LDL oxidation lag time was not shortened in comparison with healthy controls and was even prolonged at the end of cellulose acetate (P < 0.05) and cuprophane (P < 0.05) dialysis. HDL oxidation lag time increased (12.6% +/- 0.9%; P < 0.0001) 15 to 60 minutes after start of hemodialysis and returned to predialysis values thereafter. In patients with chronic renal failure, the lag time of HDL oxidation was significantly prolonged (13.34 minutes +/- 0.9) compared with healthy controls (10.91 +/- 2.0 minutes; P < 0.01) as well as compared with the dialysis patients at baseline (9.9 minutes +/- 1.4; P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Kidney Failure, Chronic/metabolism , Lipoproteins/metabolism , Renal Dialysis , Arteriosclerosis/etiology , Copper/pharmacology , Female , Humans , Kidney Failure, Chronic/therapy , Lipoproteins, HDL/metabolism , Lipoproteins, LDL/metabolism , Male , Middle Aged , Oxidation-Reduction
4.
Biochem Biophys Res Commun ; 202(1): 334-9, 1994 Jul 15.
Article in English | MEDLINE | ID: mdl-8037729

ABSTRACT

We have identified a subline of the human monocytic cell line Mono Mac 6, termed Mono Mac 6sr. Untreated Mono Mac 6sr took up and degraded [125I]-acetylated (acetyl-) and [125I]-oxidized (ox-) low-density-lipoprotein (LDL) via receptor-specific pathways. Degradation of [125I]-acetyl-LDL was saturable at a ligand concentration of approximately 10 micrograms/ml. Fucoidan and polyinosinic acid efficiently blocked [125I]-acetyl-LDL cell association, while polycytidylic acid and an excess concentration of native LDL were ineffective, suggesting the presence of scavenger receptors similar to those found in human monocyte-derived macrophages. In contrast to the Mono Mac 6sr cell line, the original Mono Mac 6 cells were scavenger receptor negative. Both cell lines specifically degraded native LDL. We conclude that Mono Mac 6sr cells constitutively take up and process modified as well as native lipoproteins and therefore could be used as a cell model in studies of human monocyte lipoprotein metabolism.


Subject(s)
Lipoproteins, LDL/metabolism , Biological Transport , Cell Line , Humans , Iodine Radioisotopes , Kinetics , Lipoproteins, LDL/isolation & purification , Monocytes
SELECTION OF CITATIONS
SEARCH DETAIL
...